Abstract:Purpose/Objective(s) Treatment de-escalation in HPV-related oropharyngeal squamous cell carcinoma (OPSCC) aims to minimize toxicity without compromising oncologic outcomes. We conducted a prospective phase II nonrandomized trial using FDG-PET imaging biomarkers to selectively de-escalate chemoradiotherapy (CRT). We hypothesized this would maintain locoregional control in all patients while decreasing toxicity in the de-escalated cohort. Materials/Methods Eligible patients had stage I-II p16+ or HPV+ OPSCC with baseline tumor FDG-PET-avidity. All were planned to receive 70 Gy to gross disease and 56 Gy to elective nodal regions in 35 fractions with concurrent weekly carboplatin/paclitaxel. Mid-treatment PET was performed at fraction 10. If metabolic tumor volume was reduced by ≥50%, CRT was completed at 54 Gy in 27 fractions. The primary objective was to demonstrate non-inferiority of 24-month locoregional recurrence (LRR) overall by comparing the upper 90% confidence interval (CI) to 25%. Secondary objectives were failure patterns, survival, ctDNA trends, mpMRI, and toxicity. Toxicity measures included patient-reported outcomes (UWQOL-RTOG, FACT-HN, XQ). Kaplan-Meier analyses were used for survival outcomes. Results Eligible patients (n = 84) were enrolled from 2018 - 2023; 90% male, 75% stage I, and 48% never-smokers. De-escalation criteria were met in 42% (n = 35). The 54 Gy cohort had fewer patients with T3 tumors (3% vs 20%, p = 0.02) and lower median baseline weight (188 vs. 207 lbs, p = 0.015); no other differences in distribution of baseline factors nor initial RT plans were found. Median follow up at this analysis was 28.9 mo overall, 31.6 mo for 54 Gy and 25.9 mo for 70 Gy patients. LRR at 24 mo was 7% (90% CI: 2% - 12.1%) in the entire cohort, 5% (90% CI: 0% – 10.5%) with 70 Gy, and 10% (90% CI: 1% - 18.2%) with 54 Gy. There were 5 LRR and 3 distant recurrences overall. Of 4 patients with only LRR, 3 were salvaged surgically without systemic therapy and have no evidence of disease, and 1 (70 Gy cohort) declined surgery. There was 1 cancer-related death after a distant-only recurrence in the 70 Gy cohort. Median weight loss from baseline in the 54 Gy cohort was significantly less at 1 mo (6.5% vs. 10.6%, p <0.001) and 3 mo (6% vs. 12.6%, p <0.001) post-RT. Use of feeding tube during RT or ≤1 mo post-RT was numerically better in 54 Gy patients (11% vs. 16%, p = 0.5). The 70 Gy cohort had one grade 4 (G4) carotid artery injury and one likely treatment-related death. The 54 Gy cohort had no G4+ toxicities, with less decrement from baseline in median UWQOL-RTOG scores for pain subscale at 1 mo (5 vs 10, p = 0.01) and mucus subscale at 12 mo (0 vs. 5, p = 0.2) post-RT. Remaining PRO instrument analyses are ongoing and will be presented. Conclusion Mid-treatment FDG-PET may be a reliable biomarker to selectively de-escalate radiation dose in early-stage HPV+ OPSCC to improve toxicity while preserving oncologic outcomes.

Randomized Clinical Trial of Tele-Surveillance and Remote Symptom Monitoring Compared to Standard Surveillance for HPV-Associated Oropharynx Cancer with No Evidence of Disease on Post-Treatment Imaging

Posttreatment surveillance PET/CT for HPV-associated oropharyngeal cancer

Impact of Surveillance Imaging in Patients With HPV-Associated Oropharyngeal Carcinoma Treated With Definitive Radiation and Chemotherapy

Follow‐up for human papillomavirus‐related oropharynx cancer concentrated on unequal symptom change (FOCUS): Prospective patient‐reported outcome collection

Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy

Multi-Center, Randomized, Controlled, Open-Label Effectiveness Study Of Primary Tumor Resection Or Not In Asymptomatic Colorectal Cancer With Unresectable Metastatic Disease.

Protocol for open-label, randomised, controlled trial of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer (SARONG trial).

Ultrasensitive Liquid Biopsy in Patients with P16-Positive Oropharyngeal Cancer Using HPV-seq

Phase II Trial Assessing Safety, Efficacy and Immune Correlates of Heterologous Prime-Boost with pBI-11 (IM) and TA-HPV (IM) Plus Pembrolizumab for Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer

Posttreatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30)

FDG-PET-based Selective De-escalation of Radiotherapy for HPV-Related Oropharynx Cancer: Results from a Phase II Trial

Lead Time to Recurrence After Posttreatment Plasma and Saliva HPV DNA Testing in Patients With Low-Risk HPV Oropharynx Cancer

Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer

Clinical Utility of Pre-Treatment and Surveillance Circulating Tumor Tissue Modified Viral HPV DNA to Detect Recurrence in a Community Based HN Cancer Program

Survival and Swallowing Function after Primary Radiotherapy versus Transoral Robotic Surgery for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma

Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer.

Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease after Chemoradiation in Cervical Cancer

An Imaging Biomarker of Tumor-Infiltrating Lymphocytes to Risk-Stratify Patients with HPV-Associated Oropharyngeal Cancer.

Does Long-term Surveillance Imaging Improve Survival in Patients Treated for Head and Neck Squamous Cell Carcinoma? A Systematic Review of the Current Evidence

Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance